Tuesday, 5 March 2019

Integrated Diagnostics Holdings Plc Notice of results

(London) – Integrated Diagnostics Holdings (“IDH,” “the Group,” or “the Company”), IDHC on the London Stock Exchange, a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, will publish its results for the year ended 31 December 2018 on Thursday 21 March 2019 at 7 am GMT.

An analyst and investor presentation will be hosted at the offices of Hudson Sandler, 25 Charterhouse Square, EC1M 6AE at 2 pm GMT on Thursday 21 March 2019. A live audio webcast will be available on the Group’s website at

Please email if you would like to attend the presentation.


IDH +20 (0)2 3345 5530

Sherif El-Ghamrawi,
Investor Relations Director
+20 (0)10 0447 8699

Hudson Sandler (International Media Relations)
+44 (0) 207 796 4133

Dan de Belder
Bertie Berger


About Integrated Diagnostics Holdings
IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group’s core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Scan (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 405 branches as of 30 June 2018, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group’s expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015.

IDH’s forward-looking strategy rests on leveraging its established business model to achieve four key strategic goals, namely: (1) continue to expand customer reach; (2) increase the number of tests per patient; (3) expand into new geographic markets through selective, value-accretive acquisitions; and (4) introduce new medical services by leveraging the Group’s network and reputable brand position. Learn more at

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit